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With the shortage of standard criteria donor (SCD) kid-
neys, efficient expanded criteria donor (ECD) kidney
utilization has become more vital. We investigated the
effects of the ECD label on kidney recovery, utilization
and outcomes. Using data from the Scientific Registry
of Transplant Recipients from November 2002 to May
2010, we determined recovery and transplant rates,
and modeled discard risk, for kidneys within a range
of kidney donor risk index (KDRI) 1.4–2.1 that included
both SCD and ECD kidneys. To further compare simi-
lar quality kidneys, these kidneys were again divided
into three KDRI intervals. Overall, ECD kidneys had
higher recovery rates, but lower transplant rates. How-
ever, within each KDRI interval, SCD and ECD kidneys
were transplanted at similar rates. Overall, there was
increased risk for discard for biopsied kidneys. SCD
kidneys in the lower two KDRI intervals had the high-
est risk of discard if biopsied. Pumped kidneys had a
lower risk of discard, which was modulated by KDRI
for SCD kidneys but not ECD kidneys. Although over-
all ECD graft survival was worse than SCD, there were
no differences within individual KDRI intervals. Thus,
ECD designation adversely affects neither utilization
nor outcomes beyond that predicted by KDRI.
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Introduction
With the ongoing organ shortage, efforts to expand the
organ pool have intensified. This has included use of ex-
panded criteria donors (ECDs), defined as all donors age
60 years or older, or those age 50–59 years who meet two
or more of the following criteria: serum creatinine >1.5
mg/dL, cerebrovascular accident as the cause of death
or history of hypertension (1). While ECD kidneys, as a
group, have inferior outcomes when compared to kidneys
from donors that do not meet the ECD definition (2), many
of these kidneys are potentially utilizable organs with ac-
ceptable outcomes. As the ECD designation suggests an
increased risk of inferior outcomes, many centers do not
list patients for ECD kidneys (3), despite a probable ben-
efit from ECD listing for a significant proportion of these
patients (4). This “labeling effect” has been hypothesized
in part based on analyses that suggest that ECD kidneys
are recovered more frequently than before the adoption
of the ECD allocation system, but are less likely to be
utilized (5).
As there is a continuum of quality for donated kidneys,
and the standard criteria donors (SCD)/ECD designation
is binary, a number of postprocurement processes have
been implemented in efforts to increase ECD utilization
while preserving outcomes, such as pulsatile perfusion and
kidney biopsy. Preprocurement risk stratification is more
useful in that it is less costly and more efficient. To this
end, Rao et al. have developed a kidney donor risk index
(KDRI) that evaluates all donor kidneys along a continuum
of risk (6). The KDRI incorporates, in addition to the ECD
risk factors, a number of other parameters that impact graft
survival, including donor factors such as diabetes, height,
weight, donation after cardiac death (DCD) status, hepatitis
C status, and transplant factors such as HLA mismatch and
en bloc or double kidney transplant. Within this formula,
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as the KDRI score increases, the percentage of ECDs that
make up a given score range increases, as these tend to be
higher risk donor kidneys. However, considerable overlap
exists between the distributions of SCD and ECD kidneys
on the KDRI spectrum, further highlighting the limitations
of the ECD designation in defining donor quality.
To address whether an ECD “labeling effect” exists, we
studied whether the ECD designation was associated with
increased risk of discard and adverse transplant outcomes
when compared to SCD kidneys of similar quality based on
the KDRI. While utilization and acceptance behavior with
respect to ECD labeling has been studied, it is not known if
kidneys with similar risk, but a different label (i.e. high KDRI
kidneys in the SCD spectrum vs. similar KDRI kidneys with
the ECD label) have different acceptance patterns.
Methods
Sample
We used data from the Scientific Registry of Transplant Recipients (SRTR)
on kidneys from deceased donors 18 years or older from November 1,
2002 to May 31, 2010 with extra ascertainment of graft failure and death
from the Centers for Medicare & Medicaid Services and the Social Security
Death Master File, respectively. From this sample, we then identified the
organs that were recovered and transplanted, and obtained for each the
corresponding recipient information. Recipient data were left missing for
organs that were recovered but not transplanted (i.e. discarded).
We arrived at our final sample in a stepwise fashion. First, because the
objectives of this study required the use of the KDRI, we aimed to make
our data similar to the data used in the initial formulation of the KDRI.
We applied certain exclusions to the data to achieve this goal. Among
transplanted organs, the exceptions were recipients less than 18 years
old, previous transplant, multiorgan transplant, ABO incompatible with the
donor, or donors with missing height, weight or creatinine level. Next, since
we were only interested in comparing two donor classifications, we further
limited our sample to include only organs from ECD and SCD (i.e. DCD
donors were excluded).
We calculated the KDRI, categorized it into deciles, and plotted it by donor
type (ECD vs. SCD). Afterward, we identified a region within which a sub-
stantial number of kidneys have the same risk index but were classified
differently (i.e. two kidneys with the same value for KDRI but one was
labeled ECD, whereas the other was labeled SCD). There were 23 203
kidneys that fell within the selected region, of which 20 246 (87.3%) were
actually recovered for transplant. Of the recovered kidneys, 13 833 (68.3%)
were transplanted, whereas 6413 (31.7%) were discarded. This KDRI over-
lap region was further divided into three interval categories (≥1.4 to ≤1.6,
>1.6 to ≤1.8 and >1.8 to ≤2.1, which represented 37.6, 30.5 and 31.9%
of the recovered kidneys, respectively).
Variables
Donor type: ECD kidneys are defined as kidneys from deceased donors
aged 50–59 years with at least two of three of the following conditions:
(1) history of hypertension, (2) serum creatinine >1.5 mg/dL and (3) death
caused by cerebrovascular accident; or donors aged 60 or older regardless
of the presence of comorbid conditions (1). For this analysis, we excluded
kidneys from all DCD donors, as well as en bloc and double kidney trans-
plants.
Kidney donor risk index: The KDRI is derived from a Cox regression model
adjusting for various donor and transplant factors that were identified to be
significant in a stepwise variable deletion process (6). KDRI is computed
using the estimates of each factor that applies to a particular deceased
donor kidney (6), including the following: age, race, history of diabetes or
hypertension, serum creatinine, height, weight, hepatitis C virus (HCV) re-
sult and cause of death. Because some of our analyses include all recovered
kidneys, whether or not they were transplanted, and because we were fo-
cusing on the effect of donor quality, we set the KDRI equation components
for DCD and en bloc/double kidney (which were excluded) and for the other
transplant-related variables (e.g. HLA mismatch and cold ischemia time) to
the value for the reference donor (KDRI = 1) so that these components did
not contribute to variations in the KDRI.
Analyses
Discard model: We modeled the probability of discard of ECD and SCD
kidneys within each of the previously defined KDRI intervals using logistic
regression. The models were also adjusted for factors not in the KDRI or
ECD definitions that could have potential effects on organ discard. We ad-
justed for donor sex (48.3% males), blood type (48.7% type O, 36% type
A, 11.8% type B and 3.5% type AB) and lifestyle habits such as having a
tattoo (11.1%), alcohol consumption (22.1%) and use of cocaine (10.9%)
or other drugs (17.9%). The majority of the data on cigarette use are miss-
ing; hence, we adjusted instead for missing information on cigarette use
(54.3%). Serology results were also factored in the analysis. For instance,
positivity on cytomegalovirus (CMV, 70.8%), hepatitis B core antibody (HB-
cAb, 9.2%) and human T cell lymphotrophic virus (HTLV, 0.1%) were utilized
as covariates. Furthermore, we adjusted for whether kidneys were pumped
(30.7%) or biopsied (78.9%).
Donors or recipient records with missing data (3.8% of total sample) were
dropped from the model (unless categorized as missing). Models were
stratified by donor type (ECD = 59.2%, SCD = 40.9%) and KDRI category.
We also examined supplementary models that tested for trends—these
models included all kidneys in the cohort (KDRI 1.4–2.1) but included an
interaction term with the KDRI interval category.
Patient survival and graft failure models: We fitted a Cox regression to
estimate the relative rate of patient death and graft failure among recipients.
Patient follow-up began on the day of transplant up to 5 years posttransplant.
Graft failure is defined as the earliest of retransplantation, return to dialysis
or patient death. In total, there were 1985 (14.4%) patient deaths and 3255
(23.5%) graft failures out of 13 833 transplanted organs. Both models were
adjusted for recipient characteristics such as sex, age, race and diabetes.
Initial steps were undertaken to assess whether the proportional hazards
assumption was met for each of the covariates. Means were assigned as
baseline values.
Similar to the discard model, the KDRI used in both the patient sur-
vival and graft failure models was the categorized KDRI (1.4–1.6, 1.6–1.8,
1.8–2.1). A model was fitted for each KDRI category, stratified by donor
type. Stratifying our analysis allowed the survival rates to vary between
strata, but assumed that the regression coefficients were the same across
strata.
All analyses were performed using SAS version 9.1.3 (SAS Institute; Cary,
NC, USA). Health Resources and Services Administration (HRSA) has deter-
mined that this study satisfies the criteria for the institutional review board
exemption described in the “Public Benefit and Service Program” provi-
sions of 45 Code of Federal Regulations 46.101(b) (5) and HRSA Circular
03.
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Figure 1: Distribution of ECD and SCD kidney donors. The boxed area represents the overlap region.
Results
This study focused on the subset of kidneys coming from
a range of KDRI values that encompassed a significant
number of both SCD and ECD kidneys (Figure 1). This
“overlap region” was composed of 23 203 kidneys, of
which 20 246 kidneys were recovered (59% were ECD
and 41% SCD). Within this cohort, ECD kidneys tended to
have higher KDRI and SCD kidneys tended to have lower
KDRI. The ECD kidneys in the overlap region were the
lower risk ECD kidneys, whereas the overlap SCD kidneys
were the upper range of risk for that group. Thus, this KDRI
overlap region was further divided into three categories
(≥1.4 to ≤1.6, >1.6 to ≤1.8 and >1.8 to ≤2.1) in efforts to
more precisely compare SCD and ECD kidneys of similar
quality.
Recipient demographics for the cohort by SCD and ECD
classification are shown in Table 1. Patients receiving ECD
kidneys were older and more likely to be white. There was
a small, but statistically significant, trend for more male
recipients in the ECD group. There were fewer ECD pa-
tients with glomerular disease, and more with diabetes,
as the listed primary etiology of renal failure. Those receiv-
ing SCD kidneys had higher panel reactive antibody (PRA)
values, both historically and at transplant, and fewer HLA
mismatches, both collectively and at each measured HLA
locus. There was a higher percentage of ECD recipients in
the A blood group, and lower in the B blood group. Cold
ischemia time was similar between the two groups.
Within the overlap range, a higher percentage of ECD kid-
neys than SCD kidneys were recovered (89.7% vs. 84.0%,
p < 0.0001); this trend was maintained within each KDRI
category (Table 2), suggesting a willingness by organ pro-
curement organizations (OPOs) and transplant centers to
recover ECD kidneys. The proportion of kidneys trans-
planted decreased with increasing KDRI category, and
was lower for ECD kidneys overall (66.1% vs. 71.6% for
SCD kidneys, p < 0.0001). However, the proportion trans-
planted, defined as organs transplanted among those re-
covered, was similar for ECD and SCD kidneys in the lower
and higher KDRI categories, and, paradoxically, was signif-
icantly greater for ECD kidneys in the 1.6–1.8 category
(71.5% vs. 63.4% for SCD kidneys, p < 0.0001), suggest-
ing that the ECD designation does not appear to adversely
affect utilization beyond that predicted by KDRI.
Adjusted models for discard were created for all kidneys in
the overlap range, and were also stratified by KDRI inter-
val (1.4–1.6, 1.6–1.8, 1.8–2.1) (Table 3). ECD kidneys were
more likely to be discarded than SCD kidneys over the
entire overlap region (odds ratio [OR] = 1.29, p < 0.0001).
However, within each KDRI interval, ECD kidneys were not
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Table 1: Recipient demographics
SCD ECD p
Age (Mean ± SD in years) 52.7 ± 11.9 59.1 ± 10.5 < 0.0001
Sex 0.04
Male 3669 (62.0%) 5043 (63.7%)
Female 2248 (38.0%) 2873 (36.3%)
Race < 0.0001
White 2265 (38.9%) 3721 (47.0%)
African American 2387 (40.3%) 2487 (31.4%)
Asian 395 (6.7%) 561 (7.1%)
Hispanic 805 (13.6%) 1004 (12.7%)
Other 65 (1.1%) 143 (1.8%)
Listed primary ESRD etiology < 0.0001
Glomerular disease 1155 (25.8%) 1136 (20.7%)
Diabetes 257 (5.8%) 472 (8.6%)
Hypertensive nephrosclerosis 1790 (40.0%) 2178 (39.7%)
Polycystic kidneys 476 (10.7%) 682 (12.4%)
Tubular & Interstitial diseases 160 (3.6%) 217 (4.0%)
Renovascular & Other vascular diseases 218 (4.9%) 270 (4.9%)
Congenital, rare familial & metabolic disorders 64 (1.4%) 51 (0.9%)
Neoplasms 0(0%) 2( < 0.1%)
Other 350 (7.8%) 474 (8.7%)
ABO < 0.0001
O 2732 (46.2%) 3787 (47.8%)
A 1949 (32.9%) 2866 (36.2%)
B 954 (16.1%) 899 (11.4%)
AB 282 (4.8%) 364 (4.6%)
Primary insurance 0.0002
Private 1624 (27.8%) 2090 (26.7%)
Medicare 3815 (65.3%) 5313 (67.8%)
Medicaid 324 (5.6%) 322 (4.1%)
Other 76 (1.3%) 107 (1.4%)
Peak PRA < 0.0001
0–9% 3956 (67.1%) 5752 (72.9%)
10–79% 1452 (24.6%) 1850 (23.4%)
80–100% 488 (8.3%) 289 (3.7%)
Peak PRA (Mean ± SD) 16.7 ± 28.3 12.0 ± 22.8 < 0.0001
Transplant PRA < 0.0001
0–9% 4779 (84.4%) 6742 (89.2%)
10–79% 716 (12.6%) 727 (9.6%)
80–100% 170 (3.0%) 90(1.2%)
Transplant PRA (Mean ± SD) 7.8 ± 20.3 4.7 ± 14.9 < 0.0001
HLA mismatch (A/B/DR) < 0.0001
0 544 (9.2%) 455 (5.8%)
1 48 (0.8%) 42 (0.53%)
2 233 (3.9%) 198 (2.5%)
3 768 (13.0%) 771 (9.7%)
4 1590 (26.9%) 1993 (25.2%)
5 1883 (31.8%) 2820 (35.6%)
6 850 (14.4%) 1635 (20.7%)
HLA-A mismatch < 0.0001
0 866 (14.6%) 916 (11.6%)
1 2128 (35.98%) 3040 (38.4%)
2 2923 (49.4%) 3959 (50.0%)
HLA-B mismatch < 0.0001
0 646 (10.9%) 598 (7.6%)
1 1423 (24.1%) 1833 (23.2%)
2 3848 (65.0%) 5484 (69.3%)
HLA-DR mismatch < 0.0001
0 1251 (21.2%) 900 (11.4%)
1 2728 (46.1%) 3151 (39.8%)
2 1937 (32.7%) 3864 (48.8%)
Cold ischemia time (Mean ± SD in h) 18.8 ± 9.4 18.9 ± 9.8 0.48
v 2 testing utilized, except for age, mean PRA, and cold ischemia—which utilized t-testing.
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Table 2: Recovered and transplanted kidneys by donor type and KDRI category
Recovered kidneys Transplanted kidneys
KDRI category SCD ECD p (v 2) SCD ECD p (v 2)
Overall (1.4–2.1) 8267 (84.0%) 11 979 (89.7%) < 0.0001 5917 (71.6%) 7916 (66.1%) < 0.0001
1.4–1.6 5058 (87.4%) 2556 (94.3%) < 0.0001 3956 (78.2%) 1969 (77.0%) 0.24
1.6–1.8 2222 (81.0%) 3963 (91.4%) < 0.0001 1408 (63.4%) 2835 (71.5%) < 0.0001
1.8–2.1 987 (75.1%) 5460 (86.5%) < 0.0001 553 (56.0%) 3112 (57.0%) 0.57
Percentage = recovered or transplanted kidneys / total kidneys of that donor type.
at increased risk of discard. In fact, in the KDRI 1.6–1.8 in-
terval, the OR of discard for ECD kidneys was 0.74 (p <
0.0001) compared to SCD kidneys.
Biopsied SCD kidneys were more frequently discarded
overall (31.8%, vs. 21.1% of unbiopsied SCD kidneys,
p < 0.0001, Table 4), and in the lower two KDRI cate-
gories (15.5% and 30.7%, vs. 25.4% and 38.7% for un-
biopsied SCD kidneys in the lower and middle categories,
p < 0.0001 and p = 0.0005, respectively). For the lower
two KDRI categories, ECD discard rates were not signifi-
cantly affected by biopsy status. In the highest KDRI cate-
gory, there was not a significant difference for SCD kidneys
(45.7% vs. 43.5% for unbiopsied SCD kidneys, p = 0.59),
whereas the rate of discard for biopsied ECD kidneys was
significantly lower than that of unbiopsied ECD kidneys
(47.6% vs. 42.4%, p = 0.02).
In the adjusted logistic model for discard (Table 5), there
were significantly higher odds of both SCD and ECD dis-
card when a biopsy was performed (OR 1.87, p < 0.0001,
and 1.21, p = 0.002, respectively), but this effect was much
more strongly modulated by KDRI among SCD kidneys
than among ECD kidneys, such that discard practice pat-
terns for biopsied SCD kidneys begin to mirror those for
ECD kidneys in the higher KDRI categories. In contrast, the
odds of ECD discard when a biopsy was performed were
not affected by KDRI. Whether or not actual biopsy re-
sults (percent glomerulosclerosis) were included in the ad-
justed logistic modeling, rather than merely biopsy status
(done/not done), the modeling was nearly identical (data
not shown).
Unadjusted discard rates were lower for pumped kidneys
compared with those not pumped for all KRDI categories of
ECD and SCD kidneys (Table 6). The differences in discard
rates between pumped and unpumped kidneys increased
with increasing KDRI for both ECD and SCD kidneys, with
almost half of unpumped kidneys discarded for both SCD
and ECD kidneys at the highest KDRI category (48.1% and
Table 3: Adjusted odds ratio for discard, stratified by KDRI category
Covariates All OR p KDRI 1.4–1.6 p KDRI 1.6–1.8 p KDRI 1.8–2.1 p
ECD 1.29 < 0.0001 1.01 0.89 0.74 < 0.0001 0.97 0.72
Biopsy not done 1.18 0.0006 0.95 0.52 1.23 0.01 1.89 < 0.0001
Biopsy missing 1.61 0.59 0.83 0.87 4.75 0.007 7.39 < 0.0001
Glomerulosclerosis (6–10%) 1.44 < 0.0001 1.57 < 0.0001 1.21 0.05 1.42 < 0.0001
Glomerulosclerosis (11–15%) 2.21 < 0.0001 1.94 < 0.0001 2.26 < 0.0001 2.23 < 0.0001
Glomerulosclerosis (16–19%) 3.44 < 0.0001 3.82 < 0.0001 3.11 < 0.0001 3.21 < 0.0001
Glomerulosclerosis (20%+) 7.67 < 0.0001 7.23 < 0.0001 7.51 < 0.0001 6.90 < 0.0001
Glomerulosclerosis missing 2.60 0.5 3.10 0.43 1.00 – 1.00 –
Male sex 1.30 < 0.0001 1.38 < 0.0001 1.32 < 0.0001 1.37 < 0.0001
Organ not pumped 1.66 < 0.0001 1.45 < 0.0001 1.84 < 0.0001 1.73 < 0.0001
Organ pumped missing 2.80 0.24 1.72 0.63 1.00 – 1.00 –
Pump resistance measure missing 1.11 0.15 1.11 0.4 1.24 0.1 1.04 0.74
Donor blood type A 1.13 0.001 1.26 0.0003 1.07 0.31 1.07 0.28
Donor blood type B 0.84 0.001 0.79 0.02 0.83 0.06 0.82 0.03
Donor blood type AB 1.54 < 0.0001 2.07 < 0.0001 1.38 0.05 1.28 0.09
Donor has tattoo 1.11 0.04 1.03 0.77 1.54 < 0.0001 0.88 0.19
Donor alcohol use 0.90 0.01 0.84 0.02 0.91 0.21 1.02 0.78
Donor cigarette use missing 0.86 < 0.0001 1.01 0.91 0.77 < 0.0001 0.79 < 0.0001
Donor cocaine use 1.28 < 0.0001 1.64 < 0.0001 1.08 0.48 0.86 0.19
Donor use of other drugs 1.14 0.006 1.15 0.06 1.10 0.27 1.29 0.004
Donor CMV positive 1.03 0.39 0.93 0.26 1.02 0.72 0.97 0.63
Donor HBcAb positive 1.56 < 0.0001 1.68 < 0.0001 1.31 0.007 1.45 < 0.0001
Donor HTLV positive 6.03 < 0.0001 7.92 0.006 4.79 0.04 5.15 0.05
Donor HBsAg 4.23 < 0.0001 6.64 0.001 4.2 × 109 1 0.85 0.79
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Table 4: Number and percentage of kidneys that were discarded,
by KDRI category, donor type and biopsy status
Biopsy Status
KDRI category SCD p ECD p
Overall (1.4–2.1)
Not biopsied 551 (21.1%) < 0.0001 534 (33.0%) 0.43
Biopsied 1799 (31.8%) 3529 (34.1%)
1.4–1.6
Not biopsied 283 (15.5%) < 0.0001 92 (20.7%) 0.22
Biopsied 819 (25.4%) 495 (23.4%)
1.6–1.8
Not biopsied 178 (30.7%) 0.0005 156 (27.3%) 0.51
Biopsied 636 (38.7%) 972 (28.7%)
1.8–2.1
Not biopsied 90 (45.7%) 0.59 286 (47.6%) 0.02
Biopsied 344 (43.5%) 2062 (42.4%)
Significance values are biopsied versus not biopsied in the same
donor type and KDRI category.
48.4%, compared to 30.4% and 33.7% for pumped SCD
and ECD kidneys, respectively). There were significantly
lower adjusted odds of both SCD and ECD discard if kid-
neys were pumped (OR 0.68, p < 0.0001, and 0.53, p <
0.0001, respectively) and, similar to the biopsy analysis, the
effect was much more strongly modulated by KDRI among
SCD kidneys than among ECD kidneys (Table 5) such that
SCD kidney discard patterns mirrored that of ECD kidneys
at higher, but not lower, KDRI values.
Finally, we sought to determine if outcomes were affected
to a greater degree by KDRI or by the SCD/ECD designa-
tion. Among transplanted kidneys, adjusted graft survival
was worse for ECD over the entire overlap range (HR =
1.13 vs. SCD, p < 0.01), but was not significantly different
within each individual KDRI category (Figure 2), suggesting
that ECD and SCD kidneys with similar KDRI values have
similar outcomes. Similarly, adjusted patient survival was
worse for ECD kidneys over the entire overlap range (HR =
1.25, p < 0.0001), but was not significantly different within
each individual KDRI category (Figure 3), suggesting no
survival difference between ECD and SCD kidneys within
a given KDRI category.
Table 6. Number and percentage of kidneys that were discarded,
by KDRI category, donor type and pump status
Pump status
KDRI category SCD p ECD p
Overall (1.4–2.1)
Not pumped 1871 (29.8%)< 0.00012961 (38.4%) < 0.0001
Pumped 479 (24.1%) 1102 (25.8%)
1.4–1.6
Not pumped 848 (22.3%) 0.17 438 (26.4%) < 0.0001
Pumped 254 (20.4%) 149 (16.7%)
1.6–1.8
Not pumped 659 (38.5%) 0.0009 848 (32.9%) < 0.0001
Pumped 155 (30.4%) 280 (20.2%)
1.8–2.1
Not pumped 364 (48.1%)< 0.0001 1675(48.4%) < 0.0001
Pumped 70 (30.4%) 673 (33.7%)
Significance values are pumped versus not pumped in the same
donor type and KDRI category.
Discussion
Deceased kidney donors have fallen to 2006 levels, and
the number of kidneys not utilized from recovered donors
remains near the recent historic peak in 2008 (7), with the
lowest transplant rates among ECD. Since the ECD/SCD
designation is binary and does not account for the spec-
trum of donor quality within each category, such data raise
the concern that the ECD label itself, rather than the actual
quality of the kidney, may adversely affect willingness to
use these kidneys (8). In fact, Hirth et al. demonstrated
that, although OPOs were recovering kidneys from donors
older than 59 years more frequently than before the ECD
era, transplant centers were using them with greater se-
lectivity (5).
With this in mind, the aim of the study was to exam-
ine the relationship of the ECD label (compared to SCD)
with utilization and outcomes at a given level of donor
risk. We found that the ECD designation does not seem
to adversely affect utilization or outcomes beyond those
predicted by the KDRI. Although ECD kidneys have higher
rates of discard and graft failure risk over the entire study
Table 5: Adjusted odds ratios for discard if biopsied or pumped, stratified by donor type and KDRI category
Biopsied (reference = unbiopsied) Pumped (reference = nonpumped)
KDRI category SCD1 p ECD1,2 p SCD3 p ECD3,4 p
Overall (1.4–2.1) 1.87 < 0.0001 1.21 0.002 0.68 < 0.0001 0.53 < 0.0001
1.4–1.6 1.93 < 0.0001 1.20 0.18 0.76 0.005 0.54 < 0.0001
1.6–1.8 1.58 < 0.0001 1.25 0.04 0.64 0.0007 0.48 < 0.0001
1.8–2.1 1.06 0.73 1.00 0.98 0.54 0.001 0.52 < 0.0001
1A stratified test for trend showed significant KDRI ∗ biopsy (est. = –0.28; p = 0.001) interaction among SCD kidneys. Nonsignificant
results were shown among ECD kidneys.
2Analysis for three-way interaction showed nonsignificant KDRI ∗ ECD ∗ biopsy interaction (est. = 0.14; p = 0.224)
3A stratified test for trend showed significant KDRI ∗ pump (est. = –0.17; p = 0.046) interaction among SCD kidneys. Nonsignificant
results were shown among ECD kidneys.
4Analysis for three-way interaction showed marginally significant KDRI ∗ ECD ∗ pump interaction (est. = 0.20; p = 0.060).
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Figure 2: Death-censored adjusted graft survival by donor type and KDRI category, with 95% confidence intervals. (A) Overall
KDRI 1.4–2.1. (B) KDRI 1.4–1.6. (C) KDRI 1.6–1.8. (D) KDRI 1.8–2.1.
population, within a given KDRI interval, the ECD desig-
nation does not confer additional risk of discard or graft
failure compared with SCD kidneys within the same inter-
val. This apparent paradox may be explained by decreasing
utilization and graft survival rates attendant with increases
in KDRI (regardless of whether kidneys are ECD or SCD),
and the differently skewed distributions of KDRI values for
ECD and SCD kidneys in the overlap range (a greater pro-
portion of ECD kidneys in the higher KDRI interval, and
of SCD kidneys in the lower interval, Figure 1). Stratifying
the study population (the overlap region of SCD and ECD
kidneys) by intervals of KDRI was critical to this analysis,
as it eliminated the effect of unequal distributions of KDRI
among SCD and ECD kidneys. Thus, the average of the
averages of these groups is not the same as the average
of the combined population.
However, the ECD label does appear to affect perceptions
of donor quality in that the effects of biopsy and pump-
ing on discard are influenced by KDRI to a greater degree
among SCD, compared to ECD kidneys. This results in sim-
ilar discard practices attributable to biopsy (higher discard
odds) and pumping (lower discard odds) for higher risk SCD
kidneys and lower risk ECD kidneys.
ECD kidneys have been shown to have a survival bene-
fit compared to dialysis, and even compared with waiting
for an SCD kidney for specific classes of recipients (pa-
tients older than 40 years in OPOs with >1350 days of
waiting list time; diabetic patients older than 40 years) (4).
Despite this, ECD designation practices vary widely, with
only about half of those predicted to benefit from ECD
actually so designated (3,9). Although patient and graft sur-
vival for ECD kidneys are lower than for SCD kidneys (10),
this can be offset by earlier ECD transplant for selected
subgroups (3,4). Although our data demonstrated lower
adjusted patient and graft survival overall, this finding was
(as was the case with utilization) primarily because ECD
kidneys tended to be at the higher end of the KDRI spec-
trum, even in our overlap region, whereas SCDs tended to
be in the lower end. In each KDRI category, survival was
not significantly different between ECD and SCDs, sup-
porting the conclusion that the ECD designation does not
predict outcomes beyond that predicted by KDRI.
Over a third of discarded kidneys are discarded due to
biopsy findings (7). Similar to previous analyses (11), we
found that, while actual biopsy results (e.g. percentage
glomerulosclerosis) strongly impacted discard rates, hav-
ing any biopsy performed resulted in increased discard
rates throughout the spectrum of our KDRI range for both
SCD and ECD kidneys. However, KDRI influenced this
biopsy effect for SCD kidneys, but not ECD kidneys, and as
the KDRI value rises for SCD kidneys, the effect of biopsy
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Figure 3: Adjusted patient survival by donor type and KDRI category, with 95% confidence intervals. (A) Overall KDRI 1.4–2.1. (B)
KDRI 1.4–1.6. (C) KDRI 1.6–1.8. (D) KDRI 1.8–2.1.
on discard seems to approach that of ECD kidneys. SCD
biopsy is usually not protocolized, but more frequently per-
formed for indication. In contrast, many OPOs biopsy all
ECD kidneys as a policy, which may account for the weak
relationship observed between biopsy and discard for ECD
kidneys. In our current study, we did not analyze outcomes
based on biopsy findings, and the impact of glomeruloscle-
rosis and other biopsy parameters on transplant outcomes
remains controversial (11).
In contrast, there is increasingly convincing data from both
observational studies and prospective trials that pulsatile
perfusion has a positive effect on outcomes. Pumped kid-
neys are discarded less frequently, are significantly less
likely to have delayed graft function (DGF), and were found
to have improved 1-year graft survival in prospective trials
(12). Favorable pump parameters strongly correlate with
lower discard rates. The overall impact of pumping on uti-
lization is difficult to discern because pumping practices
vary widely. Nevertheless, pumping was associated with
a lower discard rate for the kidneys in the KDRI overlap
region for all subgroups. For ECD kidneys, there was a
constant relationship between pumping and discard rates
across the KDRI spectrum, whereas for SCD kidneys an
increasing inverse association between pumping and dis-
card with increasing KDRI was observed. Similar to biopsy,
many OPOs pump ECD kidneys as a matter of proto-
col, whereas SCD kidneys are more frequently pumped
by request or indication, which may account for the in-
cremental effect on kidney discard that was seen with
increasing KDRI for SCD kidneys but not observed for
ECD kidneys.
This study has a number of limitations. As it uses reg-
istry data, it is dependent upon its accuracy and complete-
ness, and analyzes outcomes in a retrospective manner.
As the transplant outcomes data are based on utilized kid-
neys, the study’s conclusions about the quality of ECD
kidneys at a given KDRI are best applied to kidneys ac-
cepted under current utilization patterns. It is not known
if discarded kidneys from SCD versus ECD donors would
have similar outcomes if utilized. Although the overall co-
hort size is large, the multiple covariates and indicator
variables in a stratified analysis leave open the possibil-
ity of Type 2 statistical error, especially for the biopsy and
pumping analyses.
The findings also support the elements of the proposed kid-
ney allocation system that designate organ quality based
on a kidney donor profile index (DPI), which ranks donor kid-
neys based on KDRI, rather than ECD/SCD, since the ECD
designation does not appear to add information regard-
ing donor risk beyond that conferred by the KDRI. These
results suggest that, in a KDRI-based allocation system,
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the elimination of the ECD designation would not have a
significant impact, provided there was a mechanism for
older recipients or those with poor expected waiting list
time or posttransplant survival to be able to receive higher
KDRI organs.
However, ECD does appear to override other estimates
of donor quality (such as the other elements of KDRI), in
the utilization of biopsied and pumped kidneys; in other
words, behavior for ECD kidneys is similar regardless of
KDRI, whereas KDRI affects behavior for SCD such that
only in the highest KDRI category studied do SCD and
ECD kidneys appear to be handled similarly. Elimination of
the ECD designation may potentially improve utilization for
lower risk kidneys currently labeled ECD.
In conclusion, the ECD designation does not seem to ad-
versely affect utilization or outcomes beyond that predicted
by the KDRI. Within a given KDRI category, the ECD desig-
nation does not confer an increased graft failure risk com-
pared with SCD kidneys. The effects of biopsy and pump-
ing on discard are modulated by KDRI to a greater degree
among SCD, compared to ECD, kidneys. This results in
similar discard practices attributable to biopsy (higher dis-
card odds) and pumping (lower discard odds) among higher
risk SCD kidneys and lower risk ECD kidneys.
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